- Home
- QURE vs MGTX Comparison
QURE vs MGTX Comparison
Compare QURE & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- MGTX
- Stock Information
- Founded
- QURE 1998
- MGTX 2015
- Country
- QURE Netherlands
- MGTX United States
- Employees
- QURE N/A
- MGTX N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QURE Health Care
- MGTX Health Care
- Exchange
- QURE Nasdaq
- MGTX Nasdaq
- Market Cap
- QURE 866.3M
- MGTX 701.5M
- IPO Year
- QURE 2007
- MGTX N/A
- Fundamental
- Price
- QURE $70.00
- MGTX $9.26
- Analyst Decision
- QURE Strong Buy
- MGTX Strong Buy
- Analyst Count
- QURE 12
- MGTX 3
- Target Price
- QURE $69.67
- MGTX $25.67
- AVG Volume (30 Days)
- QURE 2.6M
- MGTX 436.9K
- Earning Date
- QURE 10-29-2025
- MGTX 11-12-2025
- Dividend Yield
- QURE N/A
- MGTX N/A
- EPS Growth
- QURE N/A
- MGTX N/A
- EPS
- QURE N/A
- MGTX N/A
- Revenue
- QURE $14,337,000.00
- MGTX $37,917,000.00
- Revenue This Year
- QURE N/A
- MGTX $144.79
- Revenue Next Year
- QURE $229.18
- MGTX $168.58
- P/E Ratio
- QURE N/A
- MGTX N/A
- Revenue Growth
- QURE N/A
- MGTX 366.84
- 52 Week Low
- QURE $5.35
- MGTX $4.55
- 52 Week High
- QURE $71.50
- MGTX $9.50
- Technical
- Relative Strength Index (RSI)
- QURE 71.31
- MGTX 63.65
- Support Level
- QURE $58.05
- MGTX $8.42
- Resistance Level
- QURE $64.75
- MGTX $9.17
- Average True Range (ATR)
- QURE 4.18
- MGTX 0.65
- MACD
- QURE -0.71
- MGTX 0.08
- Stochastic Oscillator
- QURE 89.18
- MGTX 88.38
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.